Microwave ablation combined with Gefitinib for treatment of advanced lung adenocarcinoma with EGFR mutations
10.13929/j.1672-8475.201905034
- Author:
Bo YU
1
Author Information
1. Department of Oncology, Huantai Country People's Hospital
- Publication Type:Journal Article
- Keywords:
Adenocarcinoma;
Catheter ablation;
Lung neoplasms;
Receptor, epidermal growth factor;
Tomography, X-ray computed
- From:
Chinese Journal of Interventional Imaging and Therapy
2019;16(11):668-671
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the efficacy of CT-guided microwave ablation combined with Gefitinib for treatment of advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Methods: Totally 110 patients with advanced lung adenocarcinoma of EGFR mutations were randomly divided into treatment group or control group (each n=55). All patients were treated with Gefitinib, while those in treatment group were treated with combined CT-guided microwave ablation. Clinical efficacy and adverse reactions were compared between 2 groups 6 months after treatment. Results: After 6 months of treatment, complete response (CR) and partial response (PR) were observed in 12 and 32 cases, while stable disease (SD) and progressive disease (PD) were noticed in 7 and 4 cases, respectively, and the effective rate was 80.00% (44/55), the disease control rate was 92.73% (51/55) in treatment group. Meanwhile, CR, PR, SD and PD were found in 9, 24, 10 and 12 cases, respectively, and the effective rate and disease control rate were 60.00%(33/55) and 78.18% (43/55) in control group. Both effective rate and disease control rate were higher in treatment group than in control group (all P<0.05). During 6 months' treatment, pneumothorax, hemoptysis, chest pain and fever in treatment group were more than in control group (all P<0.05), but there was no significant difference of diarrhea, rash nor hepatic insufficiency between the two groups (all P>0.05). Conclusion :CT-guided microwave ablation combined with Gefitinib is safe and effective in treatment of advanced lung adenocarcinoma with EGFR mutations.
